Verrica Pharmaceuticals Income Statement (2021-2025) | VRCA

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 12.00M0.43M0.21M8.32M0.07M0.04M0.18M2.92M1.99M3.83M5.18M1.78M0.34M3.44M12.70M14.34M
Operating items
Research & Development 5.36M3.45M3.76M3.36M2.44M3.94M2.78M3.03M2.74M5.72M6.51M5.32M4.95M3.32M2.40M1.17M2.28M1.85M2.21M
Selling, General & Administrative 6.58M7.28M8.01M5.11M5.12M5.17M3.92M3.19M4.32M5.94M20.05M17.00M16.34M16.52M16.08M9.88M8.85M8.85M9.40M
Other Operating Expenses 0.28M0.22M0.17M0.06M0.07M0.14M0.27M2.81M1.14M0.54M0.43M0.71M0.44M0.49M1.11M
Operating Expenses 11.94M10.73M11.77M8.47M7.84M9.34M6.87M6.28M7.13M11.80M26.83M25.12M22.43M20.38M18.92M11.75M11.57M11.19M12.72M
Operating Income 0.06M-10.73M-11.77M-8.47M-7.41M-9.12M1.45M-6.21M-7.09M-11.62M-23.92M-23.14M-18.60M-15.21M-20.70M-11.41M-8.13M1.51M1.63M
EBIT 0.06M-10.73M-11.77M-8.47M-7.41M-9.12M1.45M-6.21M-7.09M-11.62M-23.92M-23.14M-18.60M-15.21M-20.70M-11.41M-8.13M1.51M1.63M
Non-operating items
Interest & Investment Income 0.03M0.03M0.03M0.03M0.02M0.02M0.15M0.29M0.50M0.63M0.82M0.79M0.60M0.39M0.22M0.20M0.34M0.23M0.16M
Other Non Operating Income -0.00M-1.44M-0.05M0.04M-0.01M-0.01M-0.00M-2.63M0.25M0.60M0.03M
Non Operating Income -1.00M-1.04M-1.06M-1.07M-1.06M-1.05M-1.36M0.28M0.50M0.63M-0.89M-1.48M-1.73M-1.98M-2.16M-4.79M-1.61M-1.31M-1.90M
Net income details
EBT -0.94M-11.78M-12.83M-9.54M-8.47M-10.17M1.51M-5.92M-6.59M-10.99M-24.75M-24.65M-20.32M-17.18M-22.86M-13.55M-10.00M-0.39M-0.31M
Profit After Tax -0.94M-11.78M-12.83M-9.54M-8.47M-10.17M0.08M-5.93M-6.59M-10.99M-24.80M-24.61M-20.33M-17.19M-22.86M-16.20M-9.74M0.20M-0.27M
Income from Continuing Operations -0.94M-11.78M-12.83M-9.54M-8.47M-10.17M1.51M-5.92M-6.59M-10.99M-24.75M-24.65M-20.32M-17.18M-22.86M-13.55M-10.00M-0.39M-0.31M
Consolidated Net Income -0.94M-11.78M-12.83M-9.54M-8.47M-10.17M1.51M-5.92M-6.59M-10.99M-24.75M-24.65M-20.32M-17.18M-22.86M-13.55M-10.00M-0.39M-0.31M
Income towards Parent Company -0.94M-11.78M-12.83M-9.54M-8.47M-10.17M1.51M-5.92M-6.59M-10.99M-24.75M-24.65M-20.32M-17.18M-22.86M-13.55M-10.00M-0.39M-0.31M
Net Income towards Common Stockholders -0.94M-11.78M-12.83M-9.54M-8.47M-10.17M0.08M-5.92M-6.59M-10.99M-24.80M-24.65M-20.32M-17.19M-22.86M-13.55M-10.00M0.20M-0.31M
Additional items
EPS (Basic) -0.04-0.43-0.47-0.35-0.31-0.370.00-0.14-0.15-0.24-0.54-0.54-0.44-3.70-4.88-0.26-0.100.02-0.03
EPS (Weighted Average and Diluted) -0.43-0.47-0.35-0.31-0.370.00-0.14-0.15-0.24-0.54-0.54-0.44-3.70-4.88-0.26-0.100.02-0.03
Shares Outstanding (Weighted Average) 25.60M27.70M27.52M27.04M27.52M27.52M40.30M34.16M43.02M45.92M46.07M45.34M46.48M4.65M4.68M51.81M94.84M9.49M9.49M
Shares Outstanding (Diluted Average) 27.70M27.52M27.04M27.52M27.52M40.32M34.16M43.02M45.92M46.07M45.34M46.48M4.65M4.68M51.81M94.84M9.49M9.49M
EBITDA -0.93M-11.78M-12.83M-9.57M-8.50M-10.17M0.12M-5.90M-6.59M-10.99M-24.80M-24.61M-18.60M-15.21M-20.70M-11.41M-8.13M1.51M1.63M
Interest Expenses 1.03M1.08M1.09M1.10M1.08M1.07M0.08M1.66M2.31M2.32M2.37M2.38M2.35M2.20M2.13M2.09M